Facial Serum and Mask and Ready-to-drink Jelly From Thai Rice

February 7, 2025 updated by: Piyapong Prasertsri, Burapha University

Development and Effectiveness Evaluation of Facial Serum and Mask and Ready-to-drink Jelly From Thai Rice (Oryza Sativa L.)

This study consisted of three sub-studies including 1) development and evaluation of facial serum from Thai rice on skin moisture, elasticity, oiliness, and melanin in healthy participants 2) development and evaluation of facial mask from Thai rice on skin moisture, elasticity, oiliness, and melanin in healthy participants and 3) development and evaluation of ready-to-drink jelly from Thai rice on controlling blood glucose and endurance time in healthy participants.

Study Overview

Detailed Description

Study 1: 30 male and female participants, age 30-50 years will be randomly applied with facial serum producing from either 2% alpha albutin (standard facial serum) or Tubtim Chumphae rice extract on either right side or left side of their face daily for 12 weeks.

Study 2: 60 male and female participants, age 30-50 years will be randomly assigned into 2 groups including 1) control group (n = 30): participants will not receive any facial mask for 12 weeks and 2) treatment group (n = 30): participants will be applied with home-based program facial mask with Hom Pathum rice extract for 30 min/day, 2 days/week for 12 weeks.

Study 3: this study consists of 2 sub-studies. Study 3.1: 25 male and female participants, age 18-35 years will be randomly consumed with control jelly, jelly with Tubtim Chumphae rice, and jelly with Hom Pathum rice at 3.5 g/kg body weight. All participants will be measured for blood glucose levels before consumption and after consumption at 30, 60, 90, and 120 min. Study 3.2: 25 male and female participants, age 18-35 years will be randomly consumed with control jelly, jelly with Tubtim Chumphae rice, and jelly with Hom Pathum rice at 3.5 g/kg body weight. After each consumption, all participants will perform walking or running on treadmill at intensity of 80% maximal heart rate to measure maximal oxygen consumption.

Study Type

Interventional

Enrollment (Actual)

104

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Chonburi
      • Mueang, Chonburi, Thailand, 20131
        • Piyapong Prasertsri

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Male or female
  • Age between 18 to 50 years
  • Healthy
  • Interested in facial serum with Thai rice extract or facial mask with Thai rice extract or jelly from with Thai rice

Exclusion Criteria:

  • History of adverse effects from facial serum or mask application or jelly consumption
  • Skin allergy
  • Skin disorders
  • Skin wounds
  • History of allergy to Thai rice, particularly in Tubtim Chumpae and Hom Pathum
  • History of allergy to facial serum or mask, i.e., serum or mask from rice
  • History of allergy to gelatin
  • Signs or symptoms of fever or infection
  • Abnormal body mass index
  • Regular smokers or alcohol drinkers (>2 times per week)
  • Regular exerciser (>2 times per week or >150 min per week)
  • Regular intake of dietary supplements, i.e., vitamins, antioxidants
  • Hypertension, diabetes, cardiovascular disease, respiratory disease, endocrine disease, neuromuscular disease, musculoskeletal disease, liver disease, renal disease, immune disease, infectious disease, or cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Study 1: Facial serum with alpha albutin
Participants will be randomly applied with home-based program of facial serum producing from 2% alpha albutin (standard facial serum) on either right side or left side of their face daily for 12 weeks.
Applying with facial serum with 2% alpha albutin as active comparator daily for 12 weeks.
Experimental: Study 1: Facial serum with Tubtim Chumpae rice extract
Participants will be randomly applied with home-based program of facial serum producing from Tubtim Chumpae rice extract on either right side or left side of their face daily for 12 weeks.
Applying with facial serum with Tubtim Chumpae rice extract as experimental intervention daily for 12 weeks.
Experimental: Study 2: Facial mask with Hom Pathum rice extract
Participants will receive home-based program of facial mask with Hom Pathum rice extract for 30 min/day, 2 days/week for 12 weeks.
Applying with facial mask with Hom Pathum rice extract as experimental intervention for 30 min/day, 2 days/week for 12 weeks.
Active Comparator: Study 3: Control jelly
Participants will consume with control jelly at 3.5 g/kg body weight. Consumption will be taken at Burapha University.
Consumption with control jelly as active comparator at 3.5 g/kg body weight.
Experimental: Study 3: Jelly with Tubtim Chumpae rice
Participants will consume with Tubtim Chumpae rice jelly at 3.5 g/kg body weight. Consumption will be taken at Burapha University.
Consumption with jelly with Tubtim Chumpae rice as experimental intervention at 3.5 g/kg body weight.
Experimental: Study 3: Jelly with Hom Pathum rice
Participants will consume with Hom Pathum rice jelly at 3.5 g/kg body weight. Consumption will be taken at Burapha University.
Consumption with jelly with Hom Pathum rice as experimental intervention at 3.5 g/kg body weight.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Level of skin moisture
Time Frame: Before intervention, immediately after intervention, ends of week 4, week 8, and week 12]
Studies 1 and 2 determine level of skin moisture in arbitrary unit (no unit) using Multiprobe Adapter System with Corneometer® CM 825 probe.
Before intervention, immediately after intervention, ends of week 4, week 8, and week 12]
Level of skin elasticity
Time Frame: Before intervention, immediately after intervention, ends of week 4, week 8, and week 12]
Studies 1 and 2 determine level of skin elasticity in arbitrary unit (no unit) using Multiprobe Adapter System with Cutometer® 580 probe.
Before intervention, immediately after intervention, ends of week 4, week 8, and week 12]
Level of skin oiliness
Time Frame: Before intervention, immediately after intervention, ends of week 4, week 8, and week 12]
Studies 1 and 2 determine level of skin oiliness in arbitrary unit (no unit) using Multiprobe Adapter System with Sebumeter® SM 815 probe.
Before intervention, immediately after intervention, ends of week 4, week 8, and week 12]
Level of skin melanin
Time Frame: Before intervention, immediately after intervention, ends of week 4, week 8, and week 12]
Studies 1 and 2 determine level of skin melanin in arbitrary unit (no unit) using Multiprobe Adapter System with Mexameter® MX18 probe.
Before intervention, immediately after intervention, ends of week 4, week 8, and week 12]
Level of blood glucose
Time Frame: Before jelly consumption and after jelly consumption at 30, 60, 90, and 120 minutes
Study 3.1 determines level of blood glucose in mg/dL unit
Before jelly consumption and after jelly consumption at 30, 60, 90, and 120 minutes
Level of maximal oxygen consumption
Time Frame: After jelly consumption for 30 minutes
Study 3.2 determines level of maximal oxygen consumption in mL/kg/min unit by walking or running on treadmill at intensity of 80% maximal heart rate.
After jelly consumption for 30 minutes
Concentration of interferon-gamma
Time Frame: Before and immediately after maximal oxygen consumption test
Study 3.2 determines concentration of interferon-gamma in serum in pg (picogram)/mL unit
Before and immediately after maximal oxygen consumption test
Concentration of tumor necrosis factor-alpha
Time Frame: Before and immediately after maximal oxygen consumption test
Study 3.2 determines concentration of tumor necrosis factor-alpha in serum in pg (picogram)/mL unit
Before and immediately after maximal oxygen consumption test
Concentration of interleukin-10
Time Frame: Before and immediately after maximal oxygen consumption test
Study 3.2 determines concentration of interleukin-10 in serum in pg (picogram)/mL unit
Before and immediately after maximal oxygen consumption test
Level of superoxide dismutase activity
Time Frame: Before and immediately after maximal oxygen consumption test
Study 3.2 determines level of superoxide dismutase activity in percentage (%) unit
Before and immediately after maximal oxygen consumption test
Concentration of malondialdehyde
Time Frame: Before and immediately after maximal oxygen consumption test
Study 3.2 determines concentration of malondialdehyde in micromolar (uM) unit
Before and immediately after maximal oxygen consumption test

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Piyapong Prasertsri, Ph.D., Burapha University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2024

Primary Completion (Actual)

November 30, 2024

Study Completion (Actual)

December 31, 2024

Study Registration Dates

First Submitted

June 20, 2024

First Submitted That Met QC Criteria

June 20, 2024

First Posted (Actual)

June 26, 2024

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 7, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB1-047/2567

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There is no plan to make individual participant data available to other researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rice Serum

Clinical Trials on Study 1: Facial serum with alpha albutin

Subscribe